 Dmitri Simberg
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 28 | 2023 | 312 | 9.650 |
Why?
| | Liposomes | 17 | 2022 | 146 | 4.300 |
Why?
| | Dextrans | 12 | 2022 | 73 | 3.760 |
Why?
| | Complement C3 | 9 | 2023 | 188 | 3.370 |
Why?
| | Complement Activation | 14 | 2023 | 337 | 3.150 |
Why?
| | Drug Delivery Systems | 15 | 2023 | 295 | 3.090 |
Why?
| | Nanomedicine | 10 | 2023 | 28 | 2.450 |
Why?
| | Magnetite Nanoparticles | 9 | 2019 | 28 | 2.190 |
Why?
| | Complement System Proteins | 10 | 2023 | 281 | 2.150 |
Why?
| | Ferric Compounds | 6 | 2016 | 41 | 2.110 |
Why?
| | Drug Carriers | 9 | 2023 | 112 | 2.080 |
Why?
| | Microbubbles | 7 | 2017 | 40 | 2.030 |
Why?
| | Doxorubicin | 4 | 2022 | 286 | 1.920 |
Why?
| | Neoplastic Cells, Circulating | 4 | 2017 | 57 | 1.820 |
Why?
| | Macrophages | 8 | 2023 | 1259 | 1.690 |
Why?
| | Leukocytes | 5 | 2023 | 272 | 1.620 |
Why?
| | Ferrosoferric Oxide | 4 | 2019 | 25 | 1.480 |
Why?
| | Mice, Inbred BALB C | 17 | 2021 | 1144 | 1.450 |
Why?
| | Polyethylene Glycols | 9 | 2022 | 561 | 1.420 |
Why?
| | Receptors, Scavenger | 3 | 2016 | 16 | 1.310 |
Why?
| | Scavenger Receptors, Class A | 3 | 2019 | 9 | 1.200 |
Why?
| | Opsonin Proteins | 2 | 2019 | 25 | 1.150 |
Why?
| | Mice | 32 | 2023 | 14843 | 1.140 |
Why?
| | Cell Membrane | 4 | 2019 | 670 | 1.130 |
Why?
| | Cetuximab | 2 | 2018 | 90 | 1.110 |
Why?
| | Antibodies | 2 | 2019 | 365 | 1.100 |
Why?
| | Erythrocytes | 5 | 2019 | 568 | 1.090 |
Why?
| | Animals | 45 | 2023 | 31565 | 1.080 |
Why?
| | Immunoglobulins | 2 | 2019 | 143 | 1.020 |
Why?
| | Cell Separation | 2 | 2017 | 290 | 0.940 |
Why?
| | Antineoplastic Agents | 5 | 2019 | 1875 | 0.890 |
Why?
| | Lipids | 6 | 2022 | 564 | 0.850 |
Why?
| | Contrast Media | 3 | 2017 | 347 | 0.840 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2023 | 29 | 0.830 |
Why?
| | Receptors, Complement 3d | 1 | 2023 | 130 | 0.820 |
Why?
| | Endothelium | 2 | 2022 | 109 | 0.800 |
Why?
| | Click Chemistry | 2 | 2019 | 48 | 0.770 |
Why?
| | Phosphatidylethanolamines | 5 | 2014 | 66 | 0.770 |
Why?
| | Neoplasms | 4 | 2019 | 2086 | 0.760 |
Why?
| | Quaternary Ammonium Compounds | 5 | 2006 | 44 | 0.750 |
Why?
| | Fatty Acids, Monounsaturated | 5 | 2006 | 47 | 0.750 |
Why?
| | Complement Pathway, Alternative | 3 | 2017 | 113 | 0.750 |
Why?
| | Blood Proteins | 4 | 2019 | 222 | 0.750 |
Why?
| | Surface Properties | 7 | 2018 | 385 | 0.750 |
Why?
| | Fluorocarbons | 3 | 2013 | 94 | 0.700 |
Why?
| | Perfusion | 1 | 2020 | 147 | 0.680 |
Why?
| | Complement Inactivating Agents | 1 | 2020 | 40 | 0.680 |
Why?
| | Glioblastoma | 1 | 2022 | 250 | 0.670 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 56 | 0.660 |
Why?
| | Skin | 3 | 2020 | 653 | 0.660 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 93 | 0.650 |
Why?
| | CD55 Antigens | 1 | 2019 | 27 | 0.650 |
Why?
| | Collagen Type II | 1 | 2019 | 48 | 0.640 |
Why?
| | Protein Corona | 1 | 2019 | 4 | 0.640 |
Why?
| | Urinary Bladder | 2 | 2020 | 161 | 0.640 |
Why?
| | Cyclooctanes | 1 | 2018 | 5 | 0.630 |
Why?
| | Cell Line, Tumor | 11 | 2022 | 2700 | 0.630 |
Why?
| | Bone Marrow | 1 | 2020 | 243 | 0.630 |
Why?
| | Lymphocytes | 2 | 2020 | 327 | 0.630 |
Why?
| | Antigens, Neoplasm | 4 | 2014 | 222 | 0.620 |
Why?
| | Glioma | 1 | 2021 | 285 | 0.600 |
Why?
| | Protein Binding | 8 | 2019 | 1888 | 0.590 |
Why?
| | Transfection | 4 | 2005 | 863 | 0.590 |
Why?
| | Intravital Microscopy | 1 | 2017 | 23 | 0.580 |
Why?
| | Monocytes | 1 | 2020 | 503 | 0.570 |
Why?
| | Biological Transport | 5 | 2020 | 374 | 0.570 |
Why?
| | Cell-Penetrating Peptides | 1 | 2017 | 12 | 0.560 |
Why?
| | Phagocytes | 3 | 2023 | 90 | 0.560 |
Why?
| | Liver | 3 | 2023 | 1633 | 0.560 |
Why?
| | Skin Absorption | 1 | 2017 | 11 | 0.560 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 110 | 0.560 |
Why?
| | Lipid Bilayers | 1 | 2018 | 94 | 0.550 |
Why?
| | Inflammation Mediators | 1 | 2019 | 475 | 0.540 |
Why?
| | Particle Size | 5 | 2018 | 317 | 0.530 |
Why?
| | Mucous Membrane | 1 | 2017 | 108 | 0.530 |
Why?
| | Coated Materials, Biocompatible | 1 | 2016 | 54 | 0.530 |
Why?
| | Spectrometry, Fluorescence | 1 | 2017 | 157 | 0.530 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 305 | 0.520 |
Why?
| | Humans | 45 | 2023 | 114045 | 0.510 |
Why?
| | Fluorescent Dyes | 6 | 2021 | 298 | 0.500 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 280 | 0.500 |
Why?
| | Neutrophils | 1 | 2020 | 1089 | 0.490 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2015 | 72 | 0.490 |
Why?
| | Macrophages, Alveolar | 1 | 2018 | 348 | 0.480 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 152 | 0.480 |
Why?
| | Ligands | 2 | 2014 | 556 | 0.470 |
Why?
| | Brain Neoplasms | 1 | 2022 | 966 | 0.470 |
Why?
| | Mice, Inbred C57BL | 9 | 2021 | 4680 | 0.440 |
Why?
| | Polymers | 1 | 2017 | 448 | 0.430 |
Why?
| | Immunomagnetic Separation | 1 | 2013 | 3 | 0.430 |
Why?
| | Tissue Distribution | 4 | 2017 | 285 | 0.420 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1032 | 0.410 |
Why?
| | Complement C1q | 3 | 2022 | 36 | 0.400 |
Why?
| | Epithelial Cell Adhesion Molecule | 4 | 2017 | 10 | 0.390 |
Why?
| | Receptors, Complement 3b | 2 | 2023 | 81 | 0.390 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1002 | 0.360 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1257 | 0.360 |
Why?
| | Breast Neoplasms | 2 | 2021 | 1846 | 0.350 |
Why?
| | Immunoglobulin M | 2 | 2021 | 245 | 0.330 |
Why?
| | Kallikrein-Kinin System | 1 | 2009 | 1 | 0.330 |
Why?
| | Oxides | 1 | 2009 | 40 | 0.320 |
Why?
| | Arthritis, Experimental | 2 | 2020 | 130 | 0.300 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 87 | 0.300 |
Why?
| | Cells, Cultured | 4 | 2023 | 3861 | 0.300 |
Why?
| | Rats | 3 | 2023 | 4913 | 0.290 |
Why?
| | Female | 18 | 2021 | 59324 | 0.290 |
Why?
| | Iron | 1 | 2009 | 232 | 0.290 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 149 | 0.270 |
Why?
| | Biomimetics | 1 | 2007 | 36 | 0.270 |
Why?
| | Cholesterol | 2 | 2005 | 368 | 0.270 |
Why?
| | Cations | 3 | 2006 | 77 | 0.260 |
Why?
| | Proteomics | 2 | 2021 | 815 | 0.250 |
Why?
| | Immunoglobulin G | 2 | 2019 | 766 | 0.240 |
Why?
| | Drug Stability | 4 | 2017 | 151 | 0.240 |
Why?
| | Cell Adhesion Molecules | 3 | 2014 | 167 | 0.230 |
Why?
| | Half-Life | 2 | 2014 | 141 | 0.220 |
Why?
| | DNA, Recombinant | 1 | 2003 | 41 | 0.220 |
Why?
| | Recombinant Fusion Proteins | 2 | 2023 | 613 | 0.220 |
Why?
| | Polyamines | 3 | 2021 | 35 | 0.210 |
Why?
| | DNA | 3 | 2009 | 1350 | 0.210 |
Why?
| | Male | 13 | 2020 | 55396 | 0.210 |
Why?
| | Ultrasonics | 2 | 2014 | 46 | 0.210 |
Why?
| | Spermine | 2 | 2005 | 26 | 0.210 |
Why?
| | Injections, Intravenous | 2 | 2017 | 198 | 0.190 |
Why?
| | Microscopy, Fluorescence | 2 | 2021 | 393 | 0.190 |
Why?
| | Dendrimers | 1 | 2021 | 13 | 0.190 |
Why?
| | Temperature | 2 | 2014 | 564 | 0.190 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 98 | 0.190 |
Why?
| | Diffusion | 2 | 2019 | 119 | 0.180 |
Why?
| | Models, Molecular | 3 | 2013 | 1368 | 0.180 |
Why?
| | Single-Chain Antibodies | 1 | 2020 | 14 | 0.180 |
Why?
| | Synoviocytes | 1 | 2020 | 10 | 0.180 |
Why?
| | Dogs | 1 | 2021 | 331 | 0.180 |
Why?
| | Kupffer Cells | 2 | 2012 | 45 | 0.180 |
Why?
| | HEK293 Cells | 2 | 2013 | 590 | 0.180 |
Why?
| | Multimodal Imaging | 1 | 2020 | 89 | 0.170 |
Why?
| | Microscopy, Confocal | 1 | 2021 | 304 | 0.170 |
Why?
| | Joints | 1 | 2020 | 83 | 0.170 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 56 | 0.170 |
Why?
| | Hindlimb | 1 | 2020 | 130 | 0.170 |
Why?
| | Testis | 1 | 2020 | 133 | 0.170 |
Why?
| | Phospholipids | 1 | 2021 | 194 | 0.170 |
Why?
| | Hematinics | 1 | 2019 | 18 | 0.170 |
Why?
| | Foot | 1 | 2020 | 103 | 0.170 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2019 | 3 | 0.160 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 37 | 0.160 |
Why?
| | Carbocyanines | 1 | 2019 | 30 | 0.160 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 19 | 0.160 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 266 | 0.160 |
Why?
| | Prostate | 1 | 2020 | 157 | 0.160 |
Why?
| | Muscles | 1 | 2020 | 320 | 0.160 |
Why?
| | Magnetics | 2 | 2009 | 39 | 0.160 |
Why?
| | Femur | 1 | 2020 | 191 | 0.160 |
Why?
| | Immunity, Innate | 3 | 2023 | 720 | 0.160 |
Why?
| | Lectins | 1 | 2019 | 42 | 0.160 |
Why?
| | Jurkat Cells | 1 | 2019 | 128 | 0.160 |
Why?
| | Color | 1 | 2019 | 68 | 0.160 |
Why?
| | Molecular Structure | 2 | 2018 | 434 | 0.160 |
Why?
| | Cell Movement | 1 | 2023 | 863 | 0.160 |
Why?
| | Endothelium, Vascular | 2 | 2023 | 830 | 0.150 |
Why?
| | Opsins | 1 | 2018 | 10 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 255 | 0.150 |
Why?
| | Proteins | 2 | 2017 | 906 | 0.150 |
Why?
| | Archaeal Viruses | 1 | 2017 | 6 | 0.150 |
Why?
| | Equipment Design | 2 | 2017 | 503 | 0.150 |
Why?
| | Cartilage | 1 | 2019 | 182 | 0.140 |
Why?
| | MCF-7 Cells | 1 | 2017 | 105 | 0.140 |
Why?
| | Drug Liberation | 1 | 2017 | 25 | 0.140 |
Why?
| | Silicon Dioxide | 1 | 2018 | 88 | 0.140 |
Why?
| | Administration, Intravesical | 1 | 2017 | 14 | 0.140 |
Why?
| | Camptothecin | 1 | 2017 | 96 | 0.140 |
Why?
| | Keratins | 1 | 2017 | 176 | 0.140 |
Why?
| | Drug Compounding | 1 | 2017 | 89 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2020 | 1075 | 0.140 |
Why?
| | Optical Imaging | 1 | 2017 | 52 | 0.130 |
Why?
| | Models, Animal | 1 | 2018 | 340 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 181 | 0.130 |
Why?
| | Protein Conformation | 1 | 2019 | 803 | 0.130 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 344 | 0.130 |
Why?
| | Repressor Proteins | 1 | 2019 | 367 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 239 | 0.130 |
Why?
| | Swine | 1 | 2018 | 687 | 0.130 |
Why?
| | Sheep | 1 | 2018 | 761 | 0.130 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 8 | 0.120 |
Why?
| | Thrombosis | 2 | 2009 | 295 | 0.120 |
Why?
| | Complement Pathway, Classical | 1 | 2014 | 18 | 0.120 |
Why?
| | Endocytosis | 1 | 2015 | 146 | 0.120 |
Why?
| | Cross-Linking Reagents | 1 | 2015 | 179 | 0.120 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 24 | 0.120 |
Why?
| | Middle Aged | 3 | 2019 | 26605 | 0.120 |
Why?
| | Umbilical Veins | 1 | 2014 | 57 | 0.120 |
Why?
| | Antigen-Antibody Reactions | 1 | 2014 | 49 | 0.110 |
Why?
| | Penicillinase | 1 | 2014 | 1 | 0.110 |
Why?
| | Nanoshells | 1 | 2014 | 1 | 0.110 |
Why?
| | Bacillus cereus | 1 | 2014 | 5 | 0.110 |
Why?
| | Kinetics | 1 | 2017 | 1547 | 0.110 |
Why?
| | Lung | 3 | 2018 | 3521 | 0.110 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2014 | 22 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 347 | 0.110 |
Why?
| | Molecular Imaging | 1 | 2014 | 50 | 0.110 |
Why?
| | Models, Biological | 2 | 2019 | 1611 | 0.110 |
Why?
| | Staurosporine | 1 | 2013 | 21 | 0.110 |
Why?
| | Nanocapsules | 1 | 2013 | 8 | 0.110 |
Why?
| | Cells, Immobilized | 1 | 2013 | 21 | 0.110 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2013 | 28 | 0.110 |
Why?
| | Species Specificity | 1 | 2014 | 541 | 0.110 |
Why?
| | Blood Cells | 1 | 2013 | 38 | 0.110 |
Why?
| | Gene Expression | 2 | 2012 | 1417 | 0.110 |
Why?
| | Adult | 4 | 2019 | 30375 | 0.110 |
Why?
| | Molecular Conformation | 1 | 2013 | 135 | 0.100 |
Why?
| | Blood Platelets | 1 | 2015 | 326 | 0.100 |
Why?
| | Mice, Knockout | 2 | 2017 | 2562 | 0.100 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1311 | 0.100 |
Why?
| | Kininogens | 1 | 2012 | 4 | 0.100 |
Why?
| | Iron-Dextran Complex | 1 | 2012 | 9 | 0.100 |
Why?
| | Mannans | 1 | 2012 | 4 | 0.100 |
Why?
| | Mannose-Binding Lectins | 1 | 2012 | 12 | 0.100 |
Why?
| | Protein Kinase C | 1 | 2013 | 271 | 0.100 |
Why?
| | Lectins, C-Type | 1 | 2012 | 60 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 695 | 0.100 |
Why?
| | Collagen Type I | 1 | 2012 | 108 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 1 | 2011 | 11 | 0.090 |
Why?
| | High-Energy Shock Waves | 1 | 2011 | 4 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1735 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3498 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2012 | 522 | 0.090 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2011 | 98 | 0.090 |
Why?
| | Mice, Transgenic | 2 | 2007 | 1947 | 0.090 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 350 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 796 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 513 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 328 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2014 | 735 | 0.080 |
Why?
| | Nanostructures | 1 | 2009 | 94 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 181 | 0.070 |
Why?
| | Phosphatidylcholines | 2 | 2014 | 132 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 771 | 0.070 |
Why?
| | Carcinoma | 1 | 2009 | 198 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3039 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 4501 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2629 | 0.070 |
Why?
| | CpG Islands | 1 | 2006 | 118 | 0.070 |
Why?
| | Serum Albumin | 1 | 2005 | 137 | 0.060 |
Why?
| | Biomarkers | 1 | 2014 | 3397 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2005 | 206 | 0.060 |
Why?
| | Heparin | 1 | 2005 | 225 | 0.060 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2005 | 167 | 0.060 |
Why?
| | Micelles | 1 | 2004 | 34 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2003 | 71 | 0.050 |
Why?
| | Luciferases | 1 | 2003 | 142 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 1981 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 499 | 0.050 |
Why?
| | Glycerophospholipids | 1 | 2001 | 26 | 0.050 |
Why?
| | Mannose-Binding Lectin | 1 | 2021 | 20 | 0.050 |
Why?
| | Peptides | 1 | 2007 | 847 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2001 | 140 | 0.050 |
Why?
| | Circular Dichroism | 1 | 2001 | 135 | 0.050 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2021 | 20 | 0.050 |
Why?
| | Phagocytosis | 1 | 2023 | 349 | 0.050 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 3 | 0.050 |
Why?
| | Trastuzumab | 1 | 2021 | 89 | 0.050 |
Why?
| | Microscopy, Electron | 1 | 2001 | 408 | 0.050 |
Why?
| | Influenza Vaccines | 1 | 2005 | 497 | 0.050 |
Why?
| | Thymocytes | 1 | 2020 | 28 | 0.040 |
Why?
| | Bacteriophage lambda | 1 | 2021 | 81 | 0.040 |
Why?
| | Plasmids | 1 | 2001 | 343 | 0.040 |
Why?
| | Luminescent Proteins | 1 | 2001 | 166 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 75 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 2020 | 174 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 8 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 88 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 370 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 123 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 260 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2021 | 300 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 113 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 363 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2001 | 441 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2349 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 122 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 164 | 0.040 |
Why?
| | Immunity | 1 | 2018 | 121 | 0.040 |
Why?
| | Extremophiles | 1 | 2017 | 2 | 0.040 |
Why?
| | Sulfolobus | 1 | 2017 | 11 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2017 | 134 | 0.040 |
Why?
| | Complement Factor H | 1 | 2017 | 60 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6077 | 0.030 |
Why?
| | Lecithins | 1 | 2014 | 4 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 252 | 0.030 |
Why?
| | Inflammation | 1 | 2022 | 2464 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 628 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 341 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2272 | 0.020 |
Why?
| | Phantoms, Imaging | 1 | 2012 | 123 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1014 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1016 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 337 | 0.020 |
Why?
| | Salmon | 1 | 2006 | 12 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 137 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2005 | 11 | 0.020 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2006 | 138 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2005 | 27 | 0.020 |
Why?
| | Polyelectrolytes | 1 | 2005 | 13 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2005 | 37 | 0.020 |
Why?
| | Spermatozoa | 1 | 2006 | 84 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2005 | 75 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2005 | 40 | 0.020 |
Why?
| | Gene Transfer Techniques | 1 | 2006 | 147 | 0.020 |
Why?
| | Ceramides | 1 | 2005 | 91 | 0.020 |
Why?
| | Immunity, Mucosal | 1 | 2005 | 84 | 0.020 |
Why?
| | Genetic Therapy | 1 | 2006 | 256 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1003 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 733 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2006 | 521 | 0.010 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2005 | 138 | 0.010 |
Why?
| | Spleen | 1 | 2005 | 485 | 0.010 |
Why?
| | Cattle | 1 | 2006 | 918 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 580 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2005 | 520 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9049 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2005 | 2173 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 1824 | 0.010 |
Why?
|
|
Simberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|